medwireNews: US patients with stage IV, nonsquamous non-small-cell lung cancer (NSCLC) lacking EGFR or ALK alterations can now receive first-line treatment with atezolizumab plus nab-paclitaxel and carboplatin.
The recommended dose of atezolizumab is 1200 mg every 3 weeks and the PD-L1 inhibitor should be given first if administered on the same day as chemotherapy.
The FDA decision follows positive overall survival results from the IMpower130 trial favoring the addition of the PD-L1 inhibitor to the chemotherapeutic regimen.
In August this year the triplet regimen received a positive decision by the EMA for this indication, and the FDA previously approved atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for treatment-naïve patients with nonmutated, nonsquamous, metastatic NSCLC.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group